ClinicalTrials.gg
Not yet recruitingNCT05969392DISCOCERVUpdated Mar 11, 2025

Evaluation of Efficacy and Safety of Intradiscal Gelified Ethanol in Refractory Cervical Discogenic Pain

A Phase 2/3 interventional study of Intradiscal Gelified Ethanol (Discogel) in Pain, Cervical and Discogenic Pain, sponsored by Gelscom SAS. Not yet recruiting at 2 sites in Italy. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2025-03-11.

Sponsored by Gelscom SAS · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Neck Pain with a site in Italy — 5 open to participants now, 5 under way, 2 of them phase 3. Neck Pain · Italy.

Planned enrollment
10th of 16
60 · median 70
Started
2025
with 2 others
Phase 2/3
Only one
of the 18
Registered
13th of 18
by date
Lead sponsor
1 of 18
Gelscom SAS

Among the 18 studies in Neck Pain with a site in Italy, this one is the 10th largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2025, is the only one in phase 2/3, and was the 13th registered.

Neck Pain

1,367 studies on the registry are indexed under Neck Pain; 301 are open to participants now.

Browse Neck Pain studies →

Open to participants now

5 of the 18 studies in Neck Pain with a site in Italy are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 158 Neck Pain studies recruiting now, 25 (16%) set no upper age limit and 120 (76%) stop at 75 or younger; 8 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Neck Pain with a site in Italy, or all of them as a file.
02

Study summary

The purpose of this study is to assesse safety and efficacy of the Intradiscal Gelified Ethanol for treatment in refractory cervical discogenic pain.

Read the detailed description

After being informed about the study and potential tisks, all patients giving written informed consent will undergo a inclusion visit (CT scan and X ray at least) for study entry. At Day 0, operation with Intradiscal Gelified Ethanol will be performed by the investigator. Follow visit will be performed at 3 months and 12 months

03

Conditions studied

  • Pain, Cervical
  • Discogenic Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient 18 years or older;
  • Pain to conservative treatments for more than 2 months, non-surgical patients
  • Cervicobrachialgia due to disc herniation
  • Chronic discogenic pain (1 or 2 cervical discs) with concordant MRI;
  • Patient agreeing to participate in the study and having given written consent;
  • Patient enrolled in a health insurance plan.

Exclusion criteria

Exclusion Criteria:

  • Prior surgical treatment of the disc(s) studied;
  • Sick leave of more than 12 months secondary to painful symptoms;
  • Patient with Modic 1 score or more
  • History of cognitive-behavioral disorders that could affect the completion of self-questionnaires;
  • Local or systemic infection, or suspicion of infection;
  • Severe coagulation disorders;
  • Other inflammatory rheumatic disease;
  • Severe underlying pathology with \<1 year;
  • Women of childbearing age who are pregnant at the inclusion visit or who wish to become pregnant before the administration of the treatment (V0);
  • Known allergy to contrast material and/or local anesthetic substances;
  • Patients who cannot read or write Italian;
  • Major person benefiting from a legal protection regime (guardianship, curatorship, safeguard of justice);
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Intradiscal Gelified Ethanol Arm

    Patients who come with symptomatic cervical disc herniation or with cervical discogenic pain and meet the eligibility criteria.

    Device: Intradiscal Gelified Ethanol (Discogel)

Interventions

  • DeviceIntradiscal Gelified Ethanol (Discogel)

    Intradiscal percutaneous injection of an intradiscal Gelified Ethanol

06

What researchers measure

Primary outcomes

  1. the mean change in pain intensity assessed by a verbal local rating scale (pain intensity numerical scale) between the pre-treatment measurement (inclusion visi) and the post-treatment measurement (Visit 2 at the 3 months)

    In a 11-point numeric scale, 0 represents "NO PAIN" and 10 represents "EXTREME PAIN" (e.g., "pain as bad as you can imagine" and "worst pain imaginable").

    Time frame: 3 months

Secondary outcomes

  1. Change in pain cervical intensity using the verbal local rating scale [

    Scores range from 0-10. In a 11-point numeric scale, 0 represents "NO PAIN" and 10 represents "EXTREME PAIN" (e.g., "pain as bad as you can imagine" and "worst pain imaginable").

    Time frame: 12 months

  2. Change of consumption of painkillers

    Number, frequency and dosage of pain relief treatments will be combine todescribe the difference in painkiller consumption before and after the operation

    Time frame: 12 months

  3. Incidence of complication and adverse event rates

    Incidence of adverse event during 12 months after the treatment

    Time frame: 12 months

  4. Change in ability to manage everyday-life activity (Neck Disability Index (NDI) scale) [Time Frame : inclusion, 3 and 12 months after treatment].

    The Neck Disability Index (NDI) is used to measure pain-related disability associated with activities of daily living in people with neck pain (index between 0 and 50). The original report provided scoring intervals for interpretation, as follows: 0 - 4 = no disability, 5 - 14 = mild, 15 - 24 = moderate, 25 - 34 = severe, above 34 = complete. The NDI contains 10 items-7 related to activities of daily living, 2 related to pain, and 1 related to concentration.

    Time frame: 12 months

  5. Subjective evaluation MacNab

    The MacNab's scale is layered into 4 levels (excellent, good, fair and poor) according to the patient's well-being after surgery or procedure.The scores were divided into the following four grades: 75-100% (excellent), 50-74% (good), 25-49% (fair) and 0-24% (poor). "Excellent" is defined as "No pain; no restriction of activity". "Good" is defined as "Occasional pain of sufficient severity to interfere with the patient's ability to do his normal work or his capacity to enjoy himself in leisure hours".

    Time frame: 12 months after treatment

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No — Confidential data (Pre-market Study trial)

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2025; primary completion for Jul 2025, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2023
First posted
Aug 1, 2023
StartEst.
Apr 2025
Primary completionEst.
Jul 2025
CompletionEst.
Apr 2026
Last update
Mar 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05969392
Lead sponsor
Gelscom SAS
Responsible party
Sponsor
First posted
Aug 1, 2023
Start date
Apr 2025 (estimated)
Primary completion
Jul 2025 (estimated)
Completion
Apr 2026 (estimated)
Last update
Mar 11, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion